Cardio³ BioSciences and Mayo Clinic entered into a collaborative agreement related to the licensing of Mayo Clinic research, know-how, and intellectual property in the field of cardiac commitment of stem cells.

The research, headed by André Terzic, M.D., Ph.D., and Atta Behfar at the Mayo Clinic, has focused on the guided commitment of adult as well as embryonic stem cells. The scope of the license covers heart failure of ischemic and non-ischemic origin.

“Over one million Americans suffer a new or recurrent heart attack each year.  Despite the aggressive approaches we use to treat heart patients, no effective means are available to repair a damaged heart,” says André Terzic, M.D., Ph.D., Mayo Clinic. “Discoveries by the Mayo team open new therapeutic avenues exploiting the regenerative potential of stem cells guided toward cardiac lineage.  We are excited about translating this novel methodology into repair strategies.”

Previous articleBiomatrica and Qiagen Enter Into Marketing Agreement for Shipment and Storage Products
Next articleAmgen Makes Two Acquisitions for a Sum of $720M